These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7047926)

  • 61. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 62. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1819-30. PubMed ID: 7198459
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

  • 64. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 66. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
    Schwartzkopff W; Schilling A
    Med Welt; 1980 Dec; 31(50):1845-50. PubMed ID: 7464535
    [No Abstract]   [Full Text] [Related]  

  • 67. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Controlled trials of fish oil supplements on plasma lipid concentrations.
    Sanders TA; Mistry M
    Br J Clin Pract Suppl; 1984; 31():78-84. PubMed ID: 6091724
    [No Abstract]   [Full Text] [Related]  

  • 69. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
    Illingworth DR; Olsen GD; Cook SF; Sexton GJ; Wendel HA; Connor WE
    Atherosclerosis; 1982 Aug; 44(2):211-21. PubMed ID: 6753860
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1816-9. PubMed ID: 7198458
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Toxicological studies of plafibride. Part 4: Interaction of plafibride with other drugs.
    Zapatero J; Basi N; Vilageliu J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1835-8. PubMed ID: 7198461
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Double-blind randomized clinical study on treatment of warts with a fluorouracil-containing topical preparation (author's transl)].
    Schmidt H; Jacobsen FK
    Z Hautkr; 1981 Jan; 56(1):41-3. PubMed ID: 7013310
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of ICI 55,897 and clofibrate on platelet function and other tests abnormal in atherosclerosis.
    O'Brien JR; Etherington MD; Jamieson S; Sussex J; Shuttleworth RD
    Thromb Haemost; 1978 Aug; 40(1):75-82. PubMed ID: 364763
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
    Lasierra J; Díez MM; Fernández A; Viladés E; Gil M; Velázquez E
    Sangre (Barc); 1983; 28(6):687-95. PubMed ID: 6424250
    [No Abstract]   [Full Text] [Related]  

  • 77. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ; Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 79. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.